E1	Condition:T1 Name:T52
E2	And:T2 Arg:E1 Arg2:E3
E3	Procedure:T3
E4	Condition:T4 Name:T54
E5	Assertion:T5 Asserted:E6
E6	Procedure:T6 Name:T55
E8	Procedure:T8 Provider:E7
E9	Study:T9
E10	Condition:T10 Name:T57
E12	Observation:T12 Name:T58
E13	Observation:T13 Name:T59 Eq-Comparison:E14
E14	Eq-Comparison:T14 Operator:T60 Value:T61 Unit:T62
E15	Modifier:T15 Modifies:T63
E16	Procedure:T16 Name:T63
E17	Procedure:T17 Name:T64
E18	Or:T18 Arg:E13 Arg2:E19
E19	Observation:T19 Name:T11 Eq-Comparison:E20
E20	Eq-Comparison:T20 Operator:T65 Value:T66 Unit:T67
E21	And:T21 Arg:E19 Arg2:E23
E22	Modifier:T22 Modifies:T68
E23	Condition:T23 Name:T68
E24	Age:T24 Eq-Comparison:E25
E25	Eq-Comparison:T25 Operator:T69 Value:T70 Temporal-Unit:T71
E26	Age:T26 Eq-Comparison:E27
E27	Eq-Comparison:T27 Operator:T72 Value:T73 Temporal-Unit:T74
E28	Condition:T28 Name:T75
E29	Other:T29 Is-Other:E30
E30	Condition:T30 Name:T77 Severity:T76
E32	Condition:T32 Name:T78
E33	Condition:T33 Name:T79
E34	Condition:T34 Name:T81 Severity:T80
E35	Eq-Comparison:T35 Temporal-Period:T82
E36	Procedure:T36 Name:T84 Temporality:E35
E37	Modifier:T37 Modifies:T86
E38	Or:T38 Arg:E37 Arg2:E39
E39	Modifier:T39 Modifies:T86
E40	Procedure:T40 Name:T86
E41	Exception:T41 From:E40 Except:E45
E43	Or:T43 Arg:E31 Arg2:E44
E44	Modifier:T44 Modifies:T88
E45	Procedure:T45 Name:T88 Temporality:E46
E46	Eq-Comparison:T46 Operator:T89 Value:T90 Temporal-Unit:T91
E47	Temporal-Connection:T47 Arg:E46 Arg2:E48
E48	Study:T48
E49	Condition:T49 Name:T92
E50	Or:T50 Arg:E49 Arg2:E51
E51	Condition:T51 Name:T93
E52	Negation:T53 Negates:E3
E53	Condition:T95 Name:T96
E7	Provider:T7 Type:T56
E11	Modifier:T31 Modifies:T78
E31	Modifier:T42 Modifies:T88
E42	Condition:T83 Name:T85
E54	Drug:T87
T1	Condition 35 52	diabetes mellitus
T2	And 53 56	and
T3	Procedure 57 66	treatment
T4	Condition 73 79	CI-DME
T5	Assertion 80 89	requiring
T6	Procedure 100 107	therapy
T8	Procedure 143 152	treatment
T9	Study 201 206	study
T10	Condition 208 214	CI-DME
T12	Observation 236 262	central subfield thickness
T13	Observation 264 267	CST
T14	Eq-Comparison 269 282	> 300 microns
T15	Modifier 286 301	spectral domain
T16	Procedure 302 330	optical coherence tomography
T17	Procedure 332 338	SD-OCT
T18	Or 340 342	or
T19	Observation 343 346	CST
T20	Eq-Comparison 347 360	> 250 microns
T21	And 361 365	with
T22	Modifier 375 388	intra-retinal
T23	Condition 389 414	cystic fluid accumulation
T24	Age 450 453	age
T25	Eq-Comparison 454 464	> 18 years
T26	Age 529 532	Age
T27	Eq-Comparison 533 543	< 18 years
T28	Condition 593 627	proliferative diabetic retinopathy
T29	Other 641 646	other
T30	Condition 655 669	ocular disease
T32	Condition 683 703	macular degeneration
T33	Condition 705 713	glaucoma
T34	Condition 727 740	media opacity
T35	Eq-Comparison 743 762	history of previous
T36	Procedure 763 782	intraocular surgery
T37	Modifier 794 801	macular
T38	Or 802 804	or
T39	Modifier 805 815	panretinal
T40	Procedure 816 832	photocoagulation
T41	Exception 834 840	except
T43	Or 864 866	or
T44	Modifier 867 883	keratorefractive
T45	Procedure 884 891	surgery
T46	Eq-Comparison 892 910	more than 6 months
T47	Temporal-Connection 911 919	prior to
T48	Study 920 930	enrollment
T49	Condition 933 941	pregnant
T50	Or 942 945	and
T51	Condition 946 953	nursing
T52	Condition-Name 35 52	diabetes mellitus
T54	Condition-Name 73 79	CI-DME
T55	Procedure-Name 100 107	therapy
T57	Condition-Name 208 214	CI-DME
T58	Observation-Name 236 262	central subfield thickness
T59	Observation-Name 264 267	CST
T60	Eq-Operator 269 270	>
T61	Eq-Value 271 274	300
T62	Eq-Unit 275 282	microns
T63	Procedure-Name 302 330	optical coherence tomography
T64	Procedure-Name 332 338	SD-OCT
T65	Eq-Operator 347 348	>
T66	Eq-Value 349 352	250
T67	Eq-Unit 353 360	microns
T68	Condition-Name 389 414	cystic fluid accumulation
T69	Eq-Operator 454 455	>
T70	Eq-Value 456 458	18
T71	Eq-Temporal-Unit 459 464	years
T72	Eq-Operator 533 534	<
T73	Eq-Value 535 537	18
T74	Eq-Temporal-Unit 538 543	years
T75	Condition-Name 593 627	proliferative diabetic retinopathy
T76	Severity 647 654	serious
T77	Condition-Name 655 669	ocular disease
T78	Condition-Name 683 703	macular degeneration
T79	Condition-Name 705 713	glaucoma
T80	Severity 715 726	significant
T81	Condition-Name 727 740	media opacity
T82	Eq-Temporal-Period 743 762	history of previous
T84	Procedure-Name 763 782	intraocular surgery
T86	Procedure-Name 816 832	photocoagulation
T88	Procedure-Name 884 891	surgery
T89	Eq-Operator 892 901	more than
T90	Eq-Value 902 903	6
T91	Eq-Temporal-Unit 904 910	months
T92	Condition-Name 933 941	pregnant
T93	Condition-Name 946 953	nursing
T94	Life-Stage-And-Gender 954 959	women
T53	Negation 67 72	naÃ¯ve
T95	Condition 95 99	VEGF
T96	Condition-Name 95 99	VEGF
T7	Provider 112 130	retinal specialist
T56	Provider-Type 112 130	retinal specialist
T11	Observation-Name 343 346	CST
T31	Modifier 671 682	age-related
T42	Modifier 841 863	uncomplicated cataract
T83	Condition 967 978	sensitivity
T85	Condition-Name 967 978	sensitivity
T87	Drug 993 1015	supplement ingredients
A1	Assertion-Type-Value E5 hypothetical
A3	Temporal-Connection-Type-Value E47 before
A4	Observation-Type-Value T58 measurement
A5	Eq-Operator-Value T60 GT
A7	Eq-Operator-Value T65 GT
A8	Eq-Operator-Value T69 GT
A9	Eq-Temporal-Unit-Value T71 year
A10	Eq-Operator-Value T72 LT
A11	Eq-Temporal-Unit-Value T74 year
A12	Severity-Value T76 severe
A13	Severity-Value T80 severe
A14	Eq-Temporal-Period-Value T82 past
A16	Eq-Operator-Value T89 GT
A17	Eq-Temporal-Unit-Value T91 month
A18	Life-Stage-And-Gender-Type T94 female
R1	Treatment-For Arg1:E3 Arg2:E1
R2	Treatment-For Arg1:E6 Arg2:E53
R3	Using Arg1:E8 Arg2:E6
R4	Abbrev-Of Arg1:E13 Arg2:E12
R5	Equivalent-To Arg1:E12 Arg2:E10
R6	Found-By Arg1:E13 Arg2:E16
R7	Abbrev-Of Arg1:E17 Arg2:E16
R8	Example-Of Arg1:E32 Arg2:E30
R9	Example-Of Arg1:E33 Arg2:E30
R10	Example-Of Arg1:E34 Arg2:E30
R11	Example-Of Arg1:E40 Arg2:E36
R12	If-Then Arg1:E51 Arg2:T94
R13	Caused-By Arg1:E42 Arg2:E54